A phase 3, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus CiSPLATiN (G plus C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MiBC) (NiAGARA) Meeting Abstract
| Authors: | Kubler, H. R.; Powles, T.; Meeks, J. J.; Galsky, M.; van der Heijden, M. S.; Nishiyama, H.; Al-Ahmadie, H.; Gupta, A.; Ye, J.; Donegan, S.; Ghiorghiu, D.; Ferro, S.; Catto, J. |
| Abstract Title: | A phase 3, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus CiSPLATiN (G plus C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MiBC) (NiAGARA) |
| Meeting Title: | 34. Deutscher Krebskongress (DKK) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 43 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Feb 19-22 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2020-02-01 |
| Start Page: | 82 |
| Language: | English |
| ACCESSION: | WOS:000517158700197 |
| PROVIDER: | wos |
| DOI: | 10.1159/000506491 |
| Notes: | "34th German Cancer Congress" -- Meeting Abstract: 727 -- Source: Wos |
